Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

详细信息    查看全文

• 作者：Kunio Sugahara ; Yasuhiro Maeda ; Kyoko Shimano ; Akira Mogami ; Hirotoshi Kataoka ; Kei Ogawa ; Kumiko Hikida ; Hiroshi Kumagai ; Mahoko Asayama ; Toshinobu Yamamoto ; Tomohiko Harada ; Pingping Ni ; Shinsuke Inoue and Atsuhiro Kawaguchi
• 刊名：British Journal of Pharmacology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：174
• 期：1
• 页码：15-27
• 全文大小：703K
• ISSN：1476-5381

文摘

We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT-1303), a second-generation sphingosine 1-phosphate (S1P) receptor modulator, designed to reduce the bradycardia associated with fingolimod and other S1P receptor modulators.